Dr. Robert E. Coleman stands as a distinguished leader in the field of medical oncology with a particular focus on cancer metastasis to bone. He currently holds the position of Emeritus Professor of Medical Oncology at the University of Sheffield, where he has been instrumental in developing the city's clinical cancer research infrastructure since his arrival in 1991. A graduate of Kings College Hospital Medical School in 1978, Dr. Coleman completed his medical training in London and Edinburgh before establishing himself as a prominent figure in oncology research. Throughout his distinguished career, he has held numerous leadership positions including Deputy Chair and Board of Trustees member at St Luke's Hospice from 2010 to 2020, and service on the Board of Trustees for Breast Cancer Campaign/Breast Cancer Now from 2010 to 2018, demonstrating his commitment to both clinical care and cancer advocacy.
Dr. Coleman has established himself as a global authority in breast cancer metastasis to bone and bone biology, with his research significantly advancing the understanding of skeletal complications in cancer patients. His scholarly contributions include over 450 peer-reviewed manuscripts that have shaped clinical practice in the management of bone metastases and the bone effects of cancer treatments, including his work on mTOR inhibition with everolimus. As the past-president of the Cancer and Bone Society and founding editor of the Journal of Bone Oncology, he has played a pivotal role in establishing bone oncology as a distinct and critical subspecialty within cancer care. His expertise has directly influenced treatment guidelines and clinical approaches to managing skeletal-related events in cancer patients worldwide, improving quality of life for countless individuals facing advanced disease.
Since retiring from his formal university position in 2017, Dr. Coleman has maintained an active presence in the oncology community through continued research activities, international lectures, and consultancy work with pharmaceutical and biotechnology companies developing novel cancer therapeutics. He continues to serve the cancer community as a Board member for Weston Park Cancer Charity since 2014 and as Chair of Governors at Clifford All Saints Primary School, demonstrating his commitment to both specialized cancer care and community education. His ongoing engagement with prIME Oncology as a Medical Director from 2014-2019, developing educational activities for oncologists worldwide, underscores his dedication to advancing professional knowledge in the field. Dr. Coleman's enduring influence continues to shape the next generation of oncology research and clinical practice, ensuring that his decades of expertise remain relevant to contemporary challenges in cancer care and bone health management.
